1. Production and characterisation of a recombinant scFv reactive with human gastrointestinal carcinomas
- Author
-
Kim Dj, Suh Y, Rhim Jh, Chung Hk, Chul Woo Kim, Ryu Ys, and Chung Jh
- Subjects
Cancer Research ,SC142-reactive antigen ,Adenocarcinoma ,law.invention ,Antigen ,Antigens, Neoplasm ,Stomach Neoplasms ,law ,Escherichia coli ,Humans ,Amino Acid Sequence ,Polymerase chain reaction ,Gastrointestinal Neoplasms ,chemistry.chemical_classification ,Hybridomas ,Membrane Glycoproteins ,biology ,Immunogenicity ,Molecular and Cellular Pathology ,SC142 antibody ,expression cloning ,Molecular biology ,Recombinant Proteins ,Oncology ,chemistry ,SC142 scFv ,Expression cloning ,Immunology ,biology.protein ,Recombinant DNA ,Immunohistochemistry ,Antibody ,Glycoprotein - Abstract
SC142-reactive antigen are highly glycosylated glycoproteins expressed on tissues of gastric and colon cancers but not on normal tissues. Murine SC142 antibody specific for the SC142-reactive antigen has been produced by immunisation with SNU16 stomach cancer cells. However, SC142 antibody has several potential problems such as high immunogenicity and poor tumour penetration owing to their large size. To improve tumour penetration potential in vivo, recombinant single-chain fragments have been produced using the original hybridoma cells as a source of variable heavy- and variable light-chain-encoding antibody genes. The use of the polymerase chain reaction, expression cloning technology and gene expression systems in E. coli has led to the production of SC142 single-chain fragments, which was similar in activity to the SC142 parent antibody confirmed by immunohistochemistry. Analysis by DNA sequencing, SDS–PAGE and Western blotting has demonstrated the integrity of the single-chain fragments. Competitive ELISA showed that SC142 single-chain fragments originated from parent SC142 antibody. BIAcore biosensor binding experiments showed that the SC142 single-chain fragments had an ideal dissociation rate constant as a tumour imaging reagent. These results illustrate the potential application of these novel products as an immunodiagnostic and further immunotherapeutic reagent. British Journal of Cancer (2002) 87, 405–413. doi:10.1038/sj.bjc.6600365 www.bjcancer.com © 2002 Cancer Research UK
- Published
- 2002